85 related articles for article (PubMed ID: 10349909)
1. G-CSF-mobilized leukapheresis products: cellular characteristics and clinical performance in allografting.
Dłubek D; Pacuszko T; Suchnicki K; Lange A
J Hematother; 1999 Apr; 8(2):157-66. PubMed ID: 10349909
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
3. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
[TBL] [Abstract][Full Text] [Related]
5. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
Dreger P; Haferlach T; Eckstein V; Jacobs S; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
Br J Haematol; 1994 Jul; 87(3):609-13. PubMed ID: 7527648
[TBL] [Abstract][Full Text] [Related]
6. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
[TBL] [Abstract][Full Text] [Related]
7. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
8. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
9. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
[TBL] [Abstract][Full Text] [Related]
10. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
12. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
13. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
[TBL] [Abstract][Full Text] [Related]
14. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
[TBL] [Abstract][Full Text] [Related]
16. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
[TBL] [Abstract][Full Text] [Related]
17. Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
Sautois B; Baudoux E; Salmon JP; Michaux S; Schaaf-Lafontaine N; Pereira M; Paulus JM; Fillet G; Beguin Y
Haematologica; 2001 Nov; 86(11):1209-18. PubMed ID: 11694408
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
19. Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor.
Chen J; Burns KM; Babic A; Carrum G; Kennedy M; Segura FJ; Garcia S; Potts S; Leveque C
Transfusion; 2014 Jan; 54(1):203-10. PubMed ID: 23763340
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
